Effectiveness and safety of bisphosphonates therapy in secondary osteoporosis in children
| Autor: | Galindo Zavala, Rocío, Bou-Torrent, Rosa, Mir-Perelló, Concepción, Martínez Regueira, Soledad, Magallares-López, Berta, López-Corbeto, Mireia, en representación del Grupo de Trabajo de Osteogénesis Imperfecta y Osteoporosis Infantil Secundaria de la Sociedad Española de Reumatología Pediátrica |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Galindo Zavala R] Unidad de Pediatría, Sección Reumatología Pediátrica, Hospital Materno-Infantil de Málaga, Málaga, Spain. Grupo IBIMA Multidisciplinar de Investigación Pediátrica. [Bou-Torrent R] Unidad de Reumatología Pediátrica, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain. [Mir-Perelló C] Unidad de Pediatría, Sección de Reumatología Pediátrica, Hospital Universitari Son Espases, Servicio de Pediatría, Grupo Multidisciplinar de Pediatría (IdISBa), Palma de Mallorca, Spain. [Martínez Regueira S] Servicio de Pediatría, Complejo Hospitalario Universitario A Coruña, Hospital Teresa Herrera, A Coruña, Spain. [Magallares-López B] Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [López-Corbeto M] Unitat de Reumatologia, Secció de Reumatologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Bisfosfonatos
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Other subheadings::Other subheadings::/drug therapy [Other subheadings] Fractures Bone Bone Density Management of Technology and Innovation Efectividad Organic Chemicals::Organophosphorus Compounds::Organophosphonates::Diphosphonates [CHEMICALS AND DRUGS] Humans Treatment outcome Child Seguridad Retrospective Studies Musculoskeletal Diseases::Bone Diseases::Bone Diseases Metabolic::Osteoporosis [DISEASES] compuestos orgánicos::compuestos organofosforados::organofosfonatos::difosfonatos [COMPUESTOS QUÍMICOS Y DROGAS] Bone Density Conservation Agents Diphosphonates Bifosfonats - Ús terapèutic enfermedades musculoesqueléticas::enfermedades óseas::enfermedades óseas metabólicas::osteoporosis [ENFERMEDADES] diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Bisphosphonates Osteoporosi - Tractament Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Niño Avaluació de resultats (Assistència sanitària) Osteoporosis Safety |
| Zdroj: | Scientia |
| Popis: | Bisfosfonatos; Efectividad; Niño Bisfosfonats; Efectivitat; Nen Bisphosphonates; Effectiveness; Child Introduction There are few studies on effectiveness and safety of bisphosphonate therapy in secondary osteoporosis in children. The aim of this research was to analyse effectiveness and safety of bisphosphonates in secondary osteoporosis in children. Patients and methods Multicentre retrospective study in patients younger than 18 suffering from secondary osteoporosis and who have received bisphosphonates. Clinical data were recorded. Bone mineral density (BMD) was assessed in terms of BMD Z-score in lumbar spine (ZBMDls) measured by dual-energy X-ray absorptiometry (DXA). Effectiveness was valued at changes in ZBMDls one and two years after the onset of bisphosphonates and at the decrese in the number of fractures a year. Adverse events reported were recorded. Descriptive and bivariant analysis was performed. Results 32 patients were recruited. ZBMDls increased one year after the onset of treatment ((−2.46 ± 0.96) vs. (−1.54 ± 1.38); p < .001). Fractures a year dicreased significantly (1 (1–2) vs. 0 (0–0.61); p < .001). ZBMDls increase was higher in patients who were able to walk (1.88 ± 0.72 vs. 0.55 ± 0.82; p = .07) and correlated positively with body mass index (BMI)- for- age percentile (rho: 0.564; p < .001). The decrease in the number of fractures a year was higher in patients with lower initial fracture rate (rho: −0,47; p = .006) and with higher initial ZBMDls (rho: −0.47; p = .07). 10 adverse events were reported in 7 patients (22%), all of them intravenous bisphosphonates related. No association was found between adverse events and studied variables. Conclusions Bisphosphonates are effective in secondary osteoporosis in children. Response seems to be better in patients who are able to walk, well-nourished and in the early stages of the disease. Adverse events were frequent but mild. Introducción Los estudios sobre efectividad y seguridad de los bisfosfonatos en osteoporosis infantil secundaria (OIS) son escasos. El objetivo fue analizar efectividad y seguridad de los bisfosfonatos en OIS. Pacientes y métodos Estudio multicéntrico retrospectivo en |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|